Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Methylprednisolone
Drug ID BADD_D01433
Description Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone].[A188811] It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957.[L10785] In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression.[A192813] The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.[L12666]
Indications and Usage Adjunctive therapy for short-term administration in rheumatoid arthritis.
Marketing Status Prescription; Discontinued
ATC Code D07AA01; D10AA02; H02AB04
DrugBank ID DB00959
KEGG ID D00407
MeSH ID D008775
PubChem ID 6741
TTD Drug ID D08PIQ
NDC Product Code 69306-400; 0009-0038; 68071-5221; 71329-303; 68180-686; 57582-011; 0009-0022; 68788-4593; 22552-0029; 68382-918; 71329-305; 68180-687; 70121-1000; 82094-401; 70121-1001; 61919-149; 59746-002; 70518-1541; 68788-7833; 63629-2226; 45865-104; 68071-2370; 82094-405; 82094-403; 65162-980; 59762-0051; 70625-237; 63629-2218; 49999-153; 76420-041; 68071-2301; 59762-0049; 0009-0073; 76420-193; 68382-916; 59746-003; 71329-302; 82094-402; 71205-054; 63187-802; 59762-4440; 71205-453; 70771-1350; 59746-001; 71329-301; 70771-1351; 68180-689; 42806-400; 0781-5022; 72647-331; 60722-1003; 82094-404; 51552-0603; 68001-005; 51927-0201; 49452-4686; 68382-917; 70771-1348; 71329-304; 68382-919; 0603-4593; 65162-871; 59762-0050; 60760-373; 70786-0001; 65162-982; 70771-1349; 0009-0056; 50436-0001; 57582-101; 0009-0020; 0009-0176; 68071-4028; 59746-015; 64958-0084; 53002-3120; 82298-118; 63629-2433; 72189-264; 65162-984; 0904-6914; 69306-004; 63187-160; 50090-3811; 68084-149; 55289-649; 50090-0092; 45865-417; 50090-3094; 68180-688; 68180-685; 66267-961
Synonyms Methylprednisolone | Metipred | 6-Methylprednisolone | 6 Methylprednisolone | Urbason | Medrol
Chemical Information
Molecular Formula C22H30O5
CAS Registry Number 83-43-2
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.0030.001132%
Abscess11.01.08.0010.000495%Not Available
Acne23.02.01.001--Not Available
Addison's disease05.01.02.006; 10.04.08.008; 14.11.01.0250.000142%Not Available
Adrenal insufficiency05.01.02.001; 14.11.01.0040.000142%
Affective disorder19.04.04.001--Not Available
Agitation17.02.05.012; 19.06.02.0010.000354%
Alanine aminotransferase increased13.03.01.0030.000212%
Alkalosis14.01.02.001--
Alkalosis hypokalaemic14.01.02.002--Not Available
Alopecia23.02.02.001--
Amenorrhoea05.05.01.002; 21.01.02.001--
Amnesia17.03.02.001; 19.20.01.001--
Anaemia01.03.02.001--
Anaphylactic reaction10.01.07.001; 24.06.03.0060.000637%
Anaphylactic shock10.01.07.002; 24.06.02.0040.000212%Not Available
Anaphylactoid reaction10.01.07.003; 24.06.03.007--Not Available
Anger19.04.02.0010.000142%Not Available
Angina pectoris02.02.02.002; 24.04.04.0020.000142%
Angioedema10.01.05.009; 23.04.01.0010.000495%Not Available
Anxiety19.06.02.0020.003680%
Aphasia17.02.03.001; 19.21.01.0010.000142%
Arachnoiditis12.02.04.002; 17.06.01.0010.000212%
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.0010.001203%
Arthropathy15.01.01.003--Not Available
Asphyxia12.01.08.011; 22.02.02.0010.000142%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene